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Abstract
Background: The 7-valent pneumococcal conjugate vaccine (PCV-7) was introduced in the United Kingdom in 2006 with a
2,3 and 13month schedule, and has led to large decreases in invasive pneumococcal disease (IPD) caused by the vaccine
serotypes in both vaccinated and unvaccinated cohorts. We estimated the effectiveness of PCV-7 against IPD.
Methods and Findings: We used enhanced surveillance data, collated at the Health Protection Agency, on vaccine type
(n = 153) and non vaccine type (n = 919) IPD cases eligible for PCV-7. The indirect cohort method, a case-control type design
which uses non vaccine type cases as controls, was used to estimate effectiveness of various numbers of doses as well as for
each vaccine serotype. Possible bias with this design, caused by differential serotype replacement in vaccinated and
unvaccinated individuals, was estimated after deriving formulae to quantify the bias. The results showed good effectiveness,
increasing from 56% (95% confidence interval (CI): -7-82) for a single dose given under one year of age to 93% (95% CI: 70-
98) for two doses under one year of age plus a booster dose in the second year of life. Serotype specific estimates indicated
higher effectiveness against serotypes 4, 14 and 18C and lower effectiveness against 6B. Under the assumption of complete
serotype replacement by non vaccine serotypes in carriage, we estimated that effectiveness estimates may be
overestimated by about 2 to 5%.
Conclusions: This study shows high effectiveness of PCV-7 under the reduced schedule used in the UK. This finding agrees
with the large reductions seen in vaccine type IPD in recent years in England and Wales. The formulae derived to assess the
bias of the indirect cohort method for PCV-7 can also be used when using the design for other vaccines that affect carriage
such as the recently introduced 13 valent pneumococcal conjugate vaccine.
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Introduction
The 7-valent pneumococcal conjugate vaccine (PCV-7; Pre-
venar, Pfizer) was first licensed in the United States in 2000 as a
3+1 dose schedule following evidence of high efficacy in children
from randomized controlled trials [1]. The vaccine has since been
introduced in many countries, including the United Kingdom in
September 2006, where a reduced 2 +1 schedule at 2, 4 and13
months was used together with a single dose catch-up for children
aged between 12 and 24 months. This reduced schedule was based
on immunogenicity rather than efficacy data, and therefore
required post-licensure assessment of effectiveness [2].
Within a few years of introduction there was a considerable
reduction of vaccine-type invasive pneumococcal disease (VT -
IPD) in both the vaccine-targeted age groups and older age groups
through herd immunity in England and Wales [3]. Some of these
reductions have, however, been offset by increases in non-vaccine
type IPD (NVT – IPD) through replacement as documented in a
recent review [4]. A higher valency pneumococcal conjugate
vaccine (PCV-13, Prevenar-13, Pfizer), was introduced in the UK
from April 2010 and contains some of the serotypes that have
shown evidence of replacement [5].
The large impact of PCV-7 on IPD suggests the vaccine is
highly effective when used outside of trial settings, and this has
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been confirmed in a number of effectiveness studies evaluating the
3+1 as well as other reduced schedules. A large case-control study
in the US and two smaller case-control studies in Spain and
Canada have been conducted [6,7,8]. In addition, two studies
from the US and Germany using the indirect cohort method (also
known as the Broome method) have been published [9,10]. In this
paper we assess vaccine effectiveness (VE) of the 2+1 schedule (and
alternative reduced dose regimens) against VT-IPD as well as
against individual serotypes using enhanced surveillance data from
England and Wales. We use the indirect cohort method in which
NVT cases serve as controls [11]. This methodology, whilst useful
in providing well matched controls, is potentially subject to bias
caused by the vaccine increasing the chance of NVT carriage in
vaccinated compared to unvaccinated individuals through reduc-
tion in VT carriage and replacement by NVT carriage. The extent
to which this bias may affect VE estimates has not been considered
in previous indirect cohort studies. We derive a formula to
estimate the size of this bias and its likely impact on our estimates.
Methods
Ethics Statement
The Health Protection Agency has approval under PIAG
Section 60 of the Health and Social Act 2001 (which has subsumed
into the National Information Governance Board for Health and
Social Care with Section 60 –now Section 251 if the NHS Act
2006) to process confidential information from patients for the
purposes of monitoring the efficacy and safety of vaccination
programmes.
Study population
We used a database, set up in 1996, in which electronic data on
isolates of IPD sent to the Health Protection Agency Respiratory
and Systemic Infection Laboratory for serotyping were reconciled
with electronic reports of IPD sent to the Health Protection
Agency from laboratories in England and Wales [3,12]. This
dataset comprises cases in which S. pneumoniae has been identified
by culture, or more rarely antigen detection or polymerase chain
reaction (PCR), in either cerebrospinal or pleural fluid. Consistent
with clinical practice in the UK, blood cultures and cerebrospinal
fluid samples are almost exclusively performed on hospitalised
patients. From September 2006, vaccination status and clinical
information was sought from General Practitioners and Paedia-
tricians treating cases in the dataset that were eligible for
vaccination (i.e. individuals born since September 4th 2004). A
confirmed case of IPD was defined as a culture of pneumococcus
from a normally sterile site, or detection of pneumococcal DNA in
pleural or cerebrospinal fluid by dual target (ply and lytA)
polymerase chain reaction (PCR) together with a polysaccharide
antigen assay that detects 14 serotypes, including all those in PCV-
7 and PCV-13 [13].
In July 2010 we identified all vaccine-eligible cases with a
known serotype, a date of IPD from November 2006 to May
2010 and aged $5 months. We excluded cases where the episode
was known to be a second episode of IPD, where vaccination
status was not known and where doses were recorded as being
given prior to PCV-7 introduction in September 2006 (for
example, in another country). We also excluded cases aged less
than 14 months who were part of the one dose catch-up cohort as
very few individuals had been vaccinated, and had time for
protection to start, by this age.
Exposure to vaccine
When the vaccine was introduced in September 2006, children
who were aged ,2 months received the routine 2, 4 and13 month
schedule. Children aged 3–8 months were eligible to receive two
doses in the period before they were 12 months old followed by the
13 month booster dose. Children aged 8 months to 23 months
were eligible for the single dose catch-up once aged over twelve
months. Therefore there were a number of different schedules,
including partial vaccination whilst under the age of 12 months to
evaluate. Table 1 shows the birth cohorts and ages of cases used to
evaluate various schedules in the analysis.
Vaccine protection was defined as starting 14 days post-
vaccination accept for the booster dose where protection was
assumed after 7 days.
Explanatory variables
Information available on each case used in the analysis was
cohort (as defined in Table 1), pneumococcal serotype, prematu-
rity (gestation,37 weeks: yes/no), being in a pneumococcal risk
group (immunosupressed or asplenic / other risk group/ no risk
group), gender, ethnicity (White, Asian, Black African / Caribbean,
other) age at illness (5–6months, 7–9months, 10–13months, 14–
18months, 19–23months, 24–35months, $36months), period of
case (November 06-April 07, May 07-October 07, November 07-
April 08, May 08-October 08,November 08-April 09, May 09-
October 09, November 09-May10) and the main variable of
interest, PCV-7 vaccination status. The pneumococcal risk groups
were as defined by the UK Department of Health [14].
Statistical methods
VE was estimated as 1- odds of vaccination in a VT case / odds
of vaccination in a NVT case. Multivariable logistic regression was
used to adjust for age, gender, period, prematurity and being in a
risk group. To investigate whether VE varied by risk group and by
prematurity the significance of the interaction between vaccine
and these factors was determined. Prematurity and being in a risk
Table 1. Vaccine schedules according to birth cohort and age of IPD cases within which the schedule was evaluated.
Schedule Birth cohort Age of cases for VE
2 dose routine (2,4 months) July 2006 – December 2009 5 months to ,14 monthsa
2 dose older infants (3-8 months) February 2006 – June 2006 5 months to ,14 months
2 dose routine + booster July 2006 – December 2009 $14 months
2 dose older infants + booster February 2006 – June 2006 $14 months
1 dose catch-up September 2004-January 2006 $14 months
aThe primary schedule is evaluated using cases up to 14 months of age, after which most children have received a booster dose. The booster and 1 dose catch-up is
evaluated with cases $14 months as it is scheduled from 13 months.
doi:10.1371/journal.pone.0028435.t001
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group were only included in final models if they were both
significant and modified the vaccine effect by more than 5% since
data were incomplete for these variables in some subjects. Results
are given stratified by cohort and age, and are presented along
with 95% confidence intervals (CI).
Serotype-specific VE was also estimated using the indirect
cohort method by comparing the odds of vaccination of each
vaccine type to the non-vaccine types. To improve precision for
this analysis, VE following at least one dose was calculated, which
combined data across all cohorts. To test whether VE differed by
serotype a Fisher’s exact test was used to compare vaccination
status within vaccine serotypes. Data analysis was performed in
STATA version 10.1.
Assessment of bias in the indirect cohort method






where VEBroome is the observed VE by the indirect cohort method,
VE is the true vaccine effectiveness, pnju is the probability of non-
vaccine type carriage in an unvaccinated individual and pnjv is the
probability of non-vaccine type carriage in a vaccinated individual.
Note that in these calculations carriage is probably best
interpreted as carriage acquisition rather than carriage prevalence
because IPD is thought to occur shortly after acquisition [15]. The
two are the same if duration of carriage is the same for vaccine and
non vaccine types.
If the probability of non-vaccine type carriage is the same in
vaccinated and unvaccinated individuals (pnjv~pnju) then there is
no bias, however it has been shown that the vaccine protects
against VT carriage (carriage acquisition) [16,17] and carriage
surveys in the years following vaccination have shown overall
carriage prevalence has remained constant with NVT carriage
replacing VT carriage [18]. In highly vaccinated populations this
replacement occurs in both vaccinated and non-vaccinated
individuals through herd immunity. If we assume that carriage
replacement starts in vaccinated individuals (who are protected
against VT carriage) and then passes to unvaccinated individuals
as herd immunity effects occur, then at any point in time pnjv will
be greater than pnju and the indirect cohort method will be biased.
If we assume complete replacement at any point in time (which is
equivalent to assuming overall carriage rates remain stable and
equal in vaccinated and unvaccinated individuals) then it can be





where VEc is the effectiveness against carriage and pu is the
proportion of carriage that is vaccine type in the unvaccinated.
This formula is used along with estimates for VEc and pu to assess
the possible bias in our estimates of VE.
Results
Description of IPD cases
Out of a total of 1228 cases in vaccine eligible children aged over
5 months and with onset fromNovember 1st 2006 toMay 31st 2010,
1 was dropped as it was a second episode, 101 dropped because they
were not serotyped and 13 dropped due to vaccination status
unknown or doses given prior to September 2006. Finally 41 were
dropped who were part of the one dose-catch-up cohort but aged
less than 14 months (none had received the vaccine more than 14
days before onset). This left a total of 1072 IPD cases of which 153
Figure 1. Serotype distribution of IPD cases included in the study. Enhanced surveillance serotyped IPD cases from England and Wales with
known vaccination status from November 2006 to May 2010. Dark grey bars are PCV-7 serotypes and light grey bars non PCV-7 serotypes.
doi:10.1371/journal.pone.0028435.g001
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were VT and 919 NVT. Of these cases 127 were diagnosed by PCR
only and 945 by culture. The distribution of serotypes is shown in
Figure 1, demonstrating a predominance of NVT cases in this post
PCV-7 period, with type 19A being the most common. A
description of the 153 VT and 919 NVT cases is shown in
Table 2. Between November 2006 and May 2010 the number of
VT cases fell and the number of NVT cases increased. Vaccine
coverage increased over this period and period is, therefore, an
important confounding variable. Risk factors were present in a
significantly (p= 0.01) greater proportion of the VT cases (23%)
than NVT cases (14%). Of the VT cases where prematurity was
known 18% were premature compared to 13% of the NVT cases. If
we assume those cases where prematurity was unknown were not
premature (which is likely because prematurity is likely to be
recorded if present) these proportions reduce to 10% in both groups,
closer to the national rate of 8.6% [19].
Vaccine effectiveness
The full break down of vaccination status according to age and
doses scheduled is given in Table 3. Numbers were too small for
some scenarios to estimate VE so these were either not considered
or combined with others. Table 4 shows the VE estimates for
various schedules, including partial vaccination. VE is about 80%
for two routine doses, 55% for a single dose administered under 12
months of age and 80% for a single dose over 12 months of age in
the catch-up campaign. VE for two doses and a booster can be
calculated using different eligible vaccinated cohorts which give
alternative results. For those scheduled for two routine doses at 2
and 4 months and a booster, the numbers are small and the VE is
62% with a wide 95% CI. However if infants scheduled for
primary vaccination at older ages are added VE increases to 93%
with a relatively narrow 95% CI. This increased precision is due to
the fact that VT IPD incidence was higher in 2006/07 when the
doses were scheduled to be given to older infants and also the fact
that VE has increased to nearer 100% (which in itself increases
precision) through the addition of 7 unvaccinated cases.
Risk group and prematurity were not included when obtaining
adjusted VE estimates as they were not confounding variables,
furthermore there was no evidence of interactions between these
variables and vaccination status. Although there was no evidence
VE differed by prematurity or risk group VE was still evaluated,
where numbers were sufficient, within these groups. For
prematurity the VE of two doses given under 12 months of age
was 93% (95% CI: 72%–98%). For risk groups (combining all
together) the VE estimate was 73% (95% CI: 10%–92%) for the
one dose catch-up and 91% (95% CI: 36%–99%) for two doses
under 12 months of age. For those in the immunosuppressed /
asplenic risk group VE was 83% (95%CI: 18%–97%) for the one
dose catch-up.
Serotype specific VE estimates
Serotype specific estimates for at least one dose of vaccine are
shown in Table 5. Vaccine effectiveness differed according to
serotype (p,0.001) with the highest VE for serotypes 4, 14 and
18C and lowest VE for serotype 6B.
Assessment of bias due to replacement for the indirect
cohort method
Figure 2 shows the bias when using the indirect cohort method
under the assumption of complete replacement for a true VE of
70% and 90% and for various values of VE against carriage (VEc)
and proportion of carriage that is VT in the unvaccinated (pu).
Bias increases as VEc increases and with increasing pu. Estimates
of effectiveness against acquisition of carriage suggest this is about
50% after a booster dose or two doses given to one year olds
[16,17]. Data on carriage acquisition in unvaccinated individuals
over the study period are not available. However data are
available on carriage prevalence and show the proportion that
were VT fell from 48% to 0% in 5–20 year olds between 2001/02
and 2008/09 [18]. In under 5 year olds in 2001/02 66% of
carriage isolates were VT, but no data were available in
unvaccinated under 5 year olds in 2008/09 [18]. The proportion
of IPD cases in our population that were VT in the unvaccinated
fell from about 70% to 10% over the study period, but this may
not approximate carriage because case: carrier ratios are higher
for VTs [18]. Overall these data would suggest that averaging over
the period of this study pu is about 40% ((70%+10%)/2), which
along with VEc = 50% would mean a true VE of 90% against
IPD would be estimated at about 92.5% by the indirect cohort
method. A true VE of 70% would be estimated at about 77.5%,
however if true VE is only 70% a more realistic value forVEc is
probably 30% which would yield an observed VE of 75%.
Therefore a realistic range for the bias is probably 2 to 5% for this
study.
Table 2. Description of the 153 VT and 919 NVT IPD cases.
Factor Level VT (%) NVT(%)
Sex Female 68 (44.4%) 401(43.6%)
Male 85 (55.6%) 512 (55.7%)
Missing 0 (0%) 6 (0.7%)
Age 5–6 m 13(8.5%) 38 (4.1%)
7–9 m 23 (15.0%) 175 (19.0%)
10–13 m 19 (12.4%) 149 (16.2%)
14–18 m 31 (20.3%) 141 (15.3%)
19–23 m 20 (13.1%) 89 (9.7%)
24–35 m 25 (16.3%) 145 (15.8%)
.= 36 m 22 (14.4%) 182 (19.8%)
Period Nov06-April07 67(43.8%) 65 (7.1%)
May07-Oct07 16 (10.5%) 58 (6.3%)
Nov07-April08 28 (18.3%) 123 (13.4%)
May08-Oct08 11 (7.2%) 81 (8.8%)
Nov08-April09 12 (7.8%) 216 (23.5%)
May09-Oct09 6 (3.9%) 113 (12.3%)
Nov09-May10 13 (8.5%) 263 (28.6%)
Ethnicity Asian 8 (5.2%) 48 (5.2%)
African/Caribbean 8 (5.2%) 53 (5.8%)
Other 8 (5.2%) 64 (7.0%)
White 65 (42.5%) 577 (62.8%)
Missing 64 (41.2%) 177 (19.3%)
Risk Factor No 118 (77.1%) 762 (82.9%)
Immunosupressed / asplenic 15 (9.8%) 53 (5.8%)
Other risk factor 20 (13.1%) 76 (8.3%)
Missing 0 (0.0%) 28 (3.0%)
Born PrematureNo 74 (48.4%) 631 (68.7%)
33-36 weeks 12 (7.8%) 57 (6.2%)
,33 weeks 4 (2.6%) 35 (3.8%)
Missing 63 (41.2%) 196 (21.3%)
doi:10.1371/journal.pone.0028435.t002
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Table 3. PCV-7 vaccination status of IPD cases by age, scheduled doses and serotype.
Age Scheduled doses Vaccination status VT NVT
,14 months 2 dose routine Unvaccinated 5 17
One dose ,12 m 10 47
Two doses ,12 m 18 265
Total 33 329
2 dose older infants Unvaccinated 13 11
One dose 7 12
Two doses 2 10
Total 22 33
$14 months 2 dose routine + booster Unvaccinated 1 10
One dose ,12 m 4 7
Two doses ,12 m 3 56
One dose ,12 m + One dose .12 m 0 9
Fully vaccinateda 7 199
One dose .12 mb 0 2
Total 15 283
2 dose older infants + booster Unvaccinated 7 7
One dose ,12 m 2 4
Two doses ,12 m 0 11
One dose ,12 m+ One dose .12 m 0 4
Fully vaccinateda 0 44
One dose .12 mb 0 9
Total 9 79
1 dose catch-up Unvaccinated 53 49
One dose ,12 m 0 2
Two doses ,12 m 0 1
One dose ,12 m+ One dose .12 m 0 2
Fully vaccinateda 0 0
One dose .12 mb 21 141
Total 74 195
aFully vaccinated means at least 3 doses with one of them given at an age over 12 months. All but 4 of these are for 2 doses under 12 months and 1 dose over 12
months.
bA total of 4 individuals had more than 2 doses aged .1.
doi:10.1371/journal.pone.0028435.t003
Table 4. PCV-7 vaccine effectiveness estimates.
Age of IPD
cases Doses for VE estimate
VT cases
vaccinated / totala (%)
NVT cases





,14 months 1 dose routine/older infants 17/35 (49%)c 59/87 (68%) 55% (1–80) 56% (-7–82)
2 dose routine 18/23 (78%) 265/282 (94%) 77% (30–92) 79% (24–94)
2 dose routine/older infants 20/38 (53%) 275/303 (91%) 89% (76–95) 83% (60–93)
$14 months 2 dose routine + booster 7/8 (88%) 199/209 (95%) 65% (-214–96) 62% (-315–96)
2 dose routine/older infants + booster 7/15 (47%) 243/260 (93%) 94% (81–98) 93% (70–98)
1 dose catch-up 21/74 (28%) 141/190 (74%) 86% (75–92) 78% (56–89)
aThis is the total either unvaccinated or with the stated schedule.
bAdjusted for age, gender and period.
c17/35 comes from Table 3 as (10+7)/(10+7+5+13) where 10 and 7 are the one partial dose for routine/older infants and 5 and 13 are the unvaccinated for these groups.
doi:10.1371/journal.pone.0028435.t004
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Discussion
This analysis has shown that PCV-7 has good effectiveness
against IPD when used in a reduced schedule in England and
Wales. VE of a single dose given under one year of age is about
50%, two doses about 80%, two doses and a booster about 90%
and a single dose over one year of age about 75%. These estimates
are slightly lower than those reported from the U.S. by Whitney
et al for similar schedules of 73% (95% CI: 43%–87%) for one
dose, 96% (95% CI: 88%–99%) for two doses, 98% (95% CI:
75%–100%) for two doses and a booster and 93% (95% CI: 68%–
98%) for 1 dose in toddlers [6]. The U.S. study did, however,
report significant effectiveness against NVT IPD which is
indicative of residual confounding and hence over estimation of
VE. With the exception of a Canadian study where VE following
two doses was 99% (95% CI: 90%–100%) [7], our estimates are
consistent with those seen in other studies, although these had
small numbers and hence wide confidence intervals [8,9,10]. The
VE estimates are also consistent with the large impact on vaccine
type IPD seen in England and Wales, but should be considered in
conjuction with the overall impact seen on IPD which is partly
offset by serotype replacement [3].
The unadjusted VE estimates obtained by the indirect cohort
method were generally similar to the age, gender and period
adjusted estimates with the exception of the one dose over one year
estimate which reduced from 86% to 78%. This change is due to the
reduction in VT cases across a period of increasing vaccine coverage
and emphasizes the importance of adjusting for time period when
using the indirect cohort method. There were some differences in
serotype specific effectiveness, with a particular high VE for
serotypes 4, 14 and 18C and lower VE for serotype 6B.
The lower effectiveness for 6B is consistent with the results of
studies evaluating the immunogenicity of the two dose priming
schedule for PCV7 as used in the UK and of single catch up dose
for toddlers [20,21].
The indirect cohort method has advantages and disadvantages
compared to other methods for estimating VE post licensure such
as case-control, screening and cohort designs. A cohort design for
such a rare disease would require a population based database
with IPD serotyping results available. This may be subject to bias if
sufficient data on confounding variables are not available. The
screening method utilises vaccine coverage data, but requires this
to be unbiased and representative of the coverage expected in the
population from which the cases arose [22]. This would mean
obtaining coverage according to risk factors, exact age and
numbers of doses. Case control designs have been employed to
Table 5. Serotype specific PCV-7 vaccine effectiveness estimates for at least one dose of vaccine at any age.
Serotype
VT cases





4 1/6 (17%) 825/919 (90%) 98% (79–100) 99% (72 to 100)
6B 29/42 (69%) 825/919 (90%) 75% (45–88) 49% (-14–77)
9V 6/11 (55%) 825/919 (90%) 86% (42–97) 79% (-2–96)
14 6/37 (16%) 825/919 (90%) 98% (94–100) 93% (80–98)
18C 3/9 (33%) 825/919 (90%) 94% (73–99) 94% (64–99)
19F 20/32 (63%) 825/919 (90%) 81% (56–91) 70% (29–87)
23F 9/16 (56%) 825/919 (90%) 85% (52–95) 76% (20–93)
All VT 74/153 (48%) 825/919 (90%) 89% (84–93) 79% (67–87)
aAdjusted for age, gender, period and cohort.
doi:10.1371/journal.pone.0028435.t005
Figure 2. Assessment of bias when estimating VE with the
indirect cohort design when there is complete serotype
replacement. VEBroome is observed vaccine effectiveness by the
indirect cohort method, VEc is true vaccine effectiveness against
carriage, VE is true vaccine effectiveness (combining effectiveness
against carriage and IPD given carriage) and Pu is the proportion of
carriage that is VT in the unvaccinated. The formula relating these
quantities is VEBroome = 1 – (1-VE)/ (1 + VEc Pu / (1-Pu)). Panel A)
VE = 90%, panel B) VE = 70%.
doi:10.1371/journal.pone.0028435.g002
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estimate PCV-7 VE with controls selected from the same hospitals,
health registers and birth registers. The main disadvantage of the
case-control method is selection of appropriate controls and the
cost of obtaining controls. The advantage of the indirect cohort
method over these methods is its efficiency (it only requires
serotyped IPD cases) and the fact that the NVT cases should serve
as well-matched controls in terms of risk factors and use of health
care. One limitation is that the method may underestimate VE if
there is cross protection against NVTs. This was evaluated by
removal of potential cross-protected serotypes 6A and 19A from
the controls and this was found to make very little difference to VE
estimates, with the largest change seen for the one dose catch-up
were adjusted VE increased from 78% to 81%. The method may
also overestimate VE due to protection against VT carriage as
evaluated in this paper.
The formula provided in this paper allows calculation of the
potential bias when using the indirect cohort study for vaccines
that have herd immunity effects through carriage reduction. The
bias is at its greatest when the vaccine protection is mainly though
carriage reduction, when the vaccine types are still prevalent and
when replacement is full (and occurs rapidly). If good data are
available on carriage (or carriage acquisition) then VE estimates
could be corrected to allow for the bias. In practice such data were
not available throughout the study so the bias could only be
approximated at about 2–5% under the assumption of an average
of 40% of carriage being VT in unvaccinated individuals. This size
of bias is small compared to the precision of the VE estimates. In
time, as VT carriage reduces through herd immunity the bias
reduces, but so do VT cases with which to estimate VE. One
consequence of this potential bias would be that vaccinated
individuals would have a higher risk of NVT IPD than
unvaccinated individuals. A recent US case control study looking
at risk factors for IPD reported no such increased risk, although
point estimates for the odds ratio were not reported [23].
In summary, our results confirm that PCV-7 is a highly effective
vaccine against VT IPD and this has led to large reductions in IPD
in children in England and Wales. The indirect cohort method is a
useful and efficient design to estimate effectiveness and, for PCV-7
effectiveness estimation, biases associated with the method are
likely to be relatively small. The formulae derived to assess the bias
of the indirect cohort method can be used for other vaccines that
effect carriage such as the recently introduced 13 valent
pneumococcal conjugate vaccine.
Supporting Information
Appendix S1 Derivation of formulae to quantify bias from
replacement using the indirect cohort method.
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